Comparative Pharmacology
Head-to-head clinical analysis: BUDESONIDE versus QVAR REDIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUDESONIDE versus QVAR REDIHALER.
BUDESONIDE vs QVAR REDIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Budesonide is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting pro-inflammatory cytokines and leukocyte migration.
Beclomethasone dipropionate is a prodrug that is hydrolyzed by esterases to the active metabolite beclomethasone-17-monopropionate (17-BMP). 17-BMP is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression involved in inflammatory pathways, including inhibition of pro-inflammatory cytokines, reduction of eosinophil survival and migration, and suppression of mast cell mediators.
Inhaled: 400-800 mcg/day in 2 divided doses for asthma; oral controlled ileal release: 9 mg once daily for Crohn's disease; intranasal: 256 mcg/day in 2 sprays per nostril once daily for allergic rhinitis.
Inhalation: 40-80 mcg twice daily; maximum 320 mcg twice daily.
None Documented
None Documented
Clinical Note
moderateBudesonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin."
Clinical Note
moderateBudesonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin."
Clinical Note
moderateBudesonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin."
Clinical Note
moderateBudesonide + Trovafloxacin
2-3.6 hours (terminal elimination half-life); due to high hepatic clearance, systemic half-life is short, limiting systemic exposure.
1.5-2.0 hours (terminal half-life) after inhalation; supports twice-daily dosing.
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (~60%) and urine (~10-15%). Renal excretion of unchanged drug is negligible (<2%).
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (~64%) and urine (~12%).
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid
"The risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin."